SR 9009, also known as Stenabolic, was developed by The Scripps Investigation Institute by professor Thomas Burris, Ph.D, Professor and Director from the Center for Diabetes and Metabolic Ailments. Professor Burris does research in drug discovery development for form 1 and type two diabetes, obesity and atherosclerosis (clogged arteries), and on the relationship among circadian rhythms and metabolic ailments. He is one of the leading developers of drugs that affect metabolism and energy levels. He is also an expert on metabolic illnesses and conditions, as well as the effect of circadian rhythms upon them.

SR 9009 is a nuclear receptor reversed-viral erythroblastosis a (Rev-erba) ligand that is taken orally. It's obtainable in powder, liquid, and capsule types. Rev-erba regulates the expression of core clock proteins and for that reason aids to modulate circadian rhythm. This could affect metabolism, energy levels, stamina, and mobility.